n-acetyllactosamine has been researched along with Cirrhosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dart, AM; Du, XJ; Gao, XM; Kiriazis, H; McMullen, JR; Nguyen, MN; Su, Y; Yang, Y | 1 |
| Bank, RA; Bos, EM; de Boer, RA; Goldstein, IJ; Koerts, JA; Meissner, M; Pitt, B; Ruifrok, WP; Sanjabi, B; Silljé, HH; van der Harst, P; van Gilst, WH; van Goor, H; van Veldhuisen, DJ; Yu, L | 1 |
2 other study(ies) available for n-acetyllactosamine and Cirrhosis
| Article | Year |
|---|---|
Upregulated galectin-3 is not a critical disease mediator of cardiomyopathy induced by β
Topics: Amino Sugars; Animals; Cardiomyopathies; Disease Models, Animal; Fibrosis; Galectin 3; Genetic Predisposition to Disease; Humans; Male; Mice, Inbred C57BL; Mice, Knockout; Myocytes, Cardiac; Pectins; Phenotype; Receptors, Adrenergic, beta-2; Severity of Illness Index; Up-Regulation; Ventricular Remodeling | 2018 |
Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis.
Topics: Amino Sugars; Animals; Cardiomyopathies; Collagen Type I; Disease Models, Animal; DNA; Fibrosis; Galectin 3; Gene Expression; Heart Failure; Immunohistochemistry; Male; Mice; Mice, Knockout; Myocardium; Rats; Reverse Transcriptase Polymerase Chain Reaction; Ventricular Remodeling | 2013 |